NEW YORK, June 29, 2016 /PRNewswire/ --
The Biotech industry has seen pressure with pricing, policies,
and economic uncertainties, but still it continues to present a
number of great trades. Stock-Callers.com reviews the performances
of the following companies at yesterday's close and see if they are
worthy of consideration: Cellectar Biosciences Inc. (NASDAQ: CLRB),
Xenoport Inc. (NASDAQ: XNPT), Rexahn Pharmaceuticals Inc. (NYSE:
RNN), and Tesaro Inc. (NASDAQ: TSRO). Learn more about these stocks
and receive your complimentary trade alerts at:
http://stock-callers.com/registration
To access Stock-Callers.com full PDF Research
Packages for free, please visit the links below.
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
CLRB Research
Package: http://stock-callers.com/registration/?symbol=CLRB
XNPT Research
Package: http://stock-callers.com/registration/?symbol=XNPT
RNN Research
Package: http://stock-callers.com/registration/?symbol=RNN
TSRO Research
Package: http://stock-callers.com/registration/?symbol=TSRO
Madison, Wisconsin
headquartered clinical stage biopharmaceutical Company, Cellectar
Biosciences Inc.'s stock climbed 2.46% and finished Tuesday's
trading session at $3.33. A total
volume of 205,145 shares was traded. In the last one month, the
stock has advanced 10.26%. The Company's shares are trading above
their 50-day moving average by 29.05%. Moreover, shares of
Cellectar Biosciences, which engages in the development of targeted
phospholipid drug conjugates (PDCs) for the treatment and imaging
of cancer, have a Relative Strength Index (RSI) of 53.18.
On Tuesday, shares in Santa Clara,
California-based biopharmaceutical Company, Xenoport Inc.,
recorded a trading volume of 467,311 shares, and ended the session
0.14% higher at $7.02. The stock has
gained 59.91% in the previous three months and 27.87% on an YTD
basis. The Company's shares are trading 22.44% above their 50-day
moving average and 34.62% above their 200-day moving average.
Furthermore, shares of Xenoport, which focuses on developing and
commercializing a portfolio of product candidates for the treatment
of neurological and other disorders in the U.S., have an RSI of
78.69.
Shares in Rockville,
Maryland-based clinical stage biopharmaceutical Company,
Rexahn Pharmaceuticals Inc., closed the day at $0.26, gaining 3.14%. The stock recorded a
trading volume of 430,125 shares. The Company's shares are trading
10.51% below their 50-day moving average. Additionally, shares in
Rexahn Pharmaceuticals, which discovers, develops, and
commercializes treatments for cancer, have an RSI of 38.65.
At the closing bell yesterday, shares in Waltham, Massachusetts headquartered
oncology-focused biopharmaceutical Company, Tesaro Inc. ended 8.37%
lower at $37.21. A total volume of
1.30 million shares was traded, which was higher than their three
months average volume of 579,600 shares. The stock is trading below
its 50-day moving average by 13.86%. Furthermore, shares of Tesaro,
which identifies, acquires, develops, and commercializes cancer
therapeutics and oncology supportive care products in the U.S. and
globally, have an RSI of 37.04.
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com . Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA